BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28699297)

  • 1. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
    Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
    J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
    Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
    Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
    J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.
    Golan Y; Wolf MP; Pauker SG; Wong JB; Hadley S
    Ann Intern Med; 2005 Dec; 143(12):857-69. PubMed ID: 16365467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
    Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
    BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
    Reboli AC; Shorr AF; Rotstein C; Pappas PG; Kett DH; Schlamm HT; Reisman AL; Biswas P; Walsh TJ
    BMC Infect Dis; 2011 Sep; 11():261. PubMed ID: 21961941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.